ADAG (ADAG) Stock Price & Analysis
ADAG (ADAG) rose 4.29% to USD 3.4 as of June 10, 2026 at 05:29 UTC, according to Nexqual real-time market data.
ADAG last closed at USD 3.26; the session ranged USD 3.16–3.53 on volume of 102,496 shares. Market capitalization is $224.65M, with a 52-week range of USD 1.3–4.75 (NGM). Source: Nexqual, June 10, 2026 at 05:29 UTC.
Key Statistics (as of June 10, 2026 at 05:29 UTC)
| Price | USD 3.4 |
|---|---|
| Change | ▲ 4.29% (up) |
| Previous Close | USD 3.26 |
| Open | USD 3.28 |
| Day Range | USD 3.16 – 3.53 |
| 52-Week Range | USD 1.3 – 4.75 |
| Volume | 102,496 shares |
| Market Cap | $224.65M |
| Exchange | NGM |
Technical Analysis (ADAG)
Nexqual's technical model rates ADAG "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:29 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.82 (neutral) |
| vs SMA50 | Below (USD 3.75) |
| MACD | -0.07 (negative) |
Analyst Ratings (ADAG)
Wall Street analysts rate ADAG "None" based on 5 analysts, with a mean price target of USD 9.4 (range USD 7–14), per Nexqual as of June 10, 2026 at 05:29 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 9.4 |
| High Target | USD 14 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (ADAG)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Financials & Fundamentals (ADAG)
| Total Revenue | $7.67M |
|---|---|
| Revenue Growth (YoY) | +7332.80% |
| Gross Margin | +100.00% |
| Operating Margin | -74.96% |
| Profit Margin | -229.56% |
| ROE | -34.39% |
| Debt / Equity | 12.07 |
| Current Ratio | 3.07 |
| Total Cash | $75.84M |
| Total Debt | $6.26M |
| Free Cash Flow | $-10.25M |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Financial Health Score (ADAG)
Nexqual rates ADAG's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:29 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $76M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -34%, ROA -16.0% |
Ownership (ADAG)
| Insider Ownership | +21.16% |
|---|---|
| Institutional Ownership | +20.09% |
| Shares Outstanding | 66.07M |
| Float | 33.13M |
| Short % of Float | +2.28% |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Leadership (ADAG)
ADAG is led by Peter P. Luo (age 59), Co- Founder, Chairman, CEO and President of R & D, per Nexqual as of June 10, 2026 at 05:29 UTC.
| Co- Founder, Chairman, CEO and President of R & D | Peter P. Luo (age 59) |
|---|---|
| CFO & Director | Man Kin Tam (age 48) |
| Executive Director & Head of Human Resources | Ling Zhou |
| Chief Strategy Officer | Mickael Chane-Du |
| Executive Director of Finance | Chunfang Gu |
Major Backers & Investors (ADAG)
Notable institutional backers of ADAG include HSG Holding Ltd, Exome Asset Management LLC , Ameriprise Financial, Inc., according to Nexqual as of June 10, 2026 at 05:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HSG Holding Ltd | 2.83% |
| Exome Asset Management LLC | 1.55% |
| Ameriprise Financial, Inc. | 1.28% |
| Mill Creek Capital Advisors, LLC | 0.42% |
| Invesco | 0.2% |
| Morgan Stanley | 0.14% |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNTB | Connect Biopharma Holdings Limi | USD 2.12 | ▼ 2.3% |
| ALGS | Aligos Therapeutics, Inc. | USD 5.14 | ▲ 4.68% |
| PHVS | Pharvaris N.V. | USD 31.6 | ▲ 1.64% |
| SNSE | Sensei Biotherapeutics, Inc. | USD 12.63 | ▼ 13.79% |
| ANEB | Anebulo Pharmaceuticals Inc | USD 0.36 | ▼ 5.31% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:29 UTC. This page is informational and not investment advice.